Bonvalot, Sylvie <br/><br/>
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.  [electronic resource] 

 -  The Lancet. Oncology  08 2019 
 - 1148-1159 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(19)30326-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Female<br/>Hafnium--therapeutic use<br/>Humans<br/>Male<br/>Middle Aged<br/>Nanoparticles--therapeutic use<br/>Oxides--therapeutic use<br/>Radiation-Sensitizing Agents--therapeutic use<br/>Radiotherapy--methods<br/>Sarcoma--therapy<br/>Soft Tissue Neoplasms--therapy<br/>Young Adult